Pull to refresh
Logo
What Changed
Following Why Sign Up
Brain-activated CAR-T cells clear childhood brain tumors in mice

Brain-activated CAR-T cells clear childhood brain tumors in mice

New Capabilities

B-SYNC immune cells stay switched off until they reach the brain, then hunt tumor cells that carry two common surface proteins.

Yesterday: Findings reach wider publication

Overview

Updated 2 hours ago

Diffuse midline glioma grows into the brainstem, the tissue that controls breathing, heartbeat and swallowing. Nearly every child diagnosed with it dies within a year, and surgery cannot remove it without destroying those functions.

A team at UC San Francisco has built immune cells that travel the body switched off, then turn on only after they reach the brain. In two mouse models carrying human tumors, the treatment cleared the cancer in every animal tested.

Why it matters

DMG kills nearly every child it touches, and a therapy that activates only inside the brain could reach tumors that surgery and drugs cannot.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

100%
Mice whose DMG tumors cleared
Complete tumor elimination in every mouse tested across two human DMG models, using direct injection into the brain.
70+ days
Engineered cells still functional
B-SYNC cells were still patrolling for cancer more than ten weeks after treatment.
20%
Glioblastoma patients with the old target
The earlier E-SYNC design depended on EGFRvIII, a mutation present in only about a fifth of patients.
~1 year
Typical survival after DMG diagnosis
Nearly all children diagnosed with diffuse midline glioma die within a year.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

HO
Hideho Okada
Neurosurgeon and immunologist, UC San Francisco
Preparing first human trials of B-SYNC
WL
Wendell Lim
Professor of Cellular and Molecular Pharmacology, UC San Francisco
Co-developer of the synNotch control system
SL
Senthilnath Lakshmanachetty
Postdoctoral researcher, Okada lab
Ran the B-SYNC mouse experiments
 Sabine Mueller
Sabine Mueller
Pediatric neuro-oncologist, UC San Francisco
Slated to co-lead the first B-SYNC trial
MJ
Marie Jaeger-Krause
Physician, UC San Francisco
Slated to co-lead the first B-SYNC trial

Organizations Involved

UC San Francisco
UC San Francisco
Academic medical center
Developer of the B-SYNC therapy

A research university and hospital system whose immunology and neurosurgery labs built the synNotch CAR-T platform.

Timeline

2021 November 2026

4 events Latest: Yesterday
Tap a bar to jump to that date

  1. Findings reach wider publication

    Latest Publication

    ScienceDaily publishes the mouse results, bringing the therapy to a broader lay audience.

  2. B-SYNC clears DMG tumors in every mouse tested

    Research

    UCSF reports complete tumor elimination in two human DMG mouse models, with cells still active past 70 days.

  3. Stanford reports tumor shrinkage in children with DMG

    Clinical trial

    Four patients had tumor volume reduced by more than half; one tumor disappeared from scans.

  4. First-generation synNotch CAR-T for glioblastoma

    Research

    Okada and Lim report E-SYNC, which senses the EGFRvIII mutation before producing a tumor-targeting receptor.

Scenarios

1

First B-SYNC trial opens and enrolls children

Likely Resolves by Q2 2028

Discussed by: UC San Francisco researchers preparing the protocol

Okada, Lim and their clinical partners convert the mouse work into a human study, using each patient's own modified T cells. The protocol tests intravenous delivery against direct injection into the brain's ventricles, with a shunt and scalp reservoir allowing repeat doses.

2

B-SYNC shrinks tumors in children, not just mice

Uncertain Resolves by End of 2030

Discussed by: UCSF investigators and outside CAR-T researchers

The mouse data show the mechanism works in animals but say nothing about safety or efficacy in people. A small early-phase study would look for tumor shrinkage and for the neurologic side effects that have complicated other brain CAR-T efforts.

3

Trial stalls before the first patient is dosed

Possible Resolves by End of 2029

Discussed by: Manufacturing and cell-therapy analysts

Each dose must be engineered from a patient's own T cells and, in the brain-injection arm, delivered through implanted hardware. Either step can fail: cell manufacturing, regulatory review, or surgical logistics.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2021

E-SYNC glioblastoma therapy (2021)

Okada and Lim built a CAR-T cell that used a synNotch sensor to detect EGFRvIII, a mutated protein on some glioblastoma cells, before producing a receptor for two other tumor proteins. The two-step design beat single-step CAR-T in the lab.

Then

The approach worked but only for the roughly 20% of patients whose tumors carry EGFRvIII.

Now

Tumors could shed the mutation and escape, which pushed the team to find a more stable trigger.

Why this matters now

B-SYNC is the direct successor, swapping a tumor mutation for brevican, a protein found throughout the brain.

November 2024

Stanford CAR-T trial for DMG (2024)

A Stanford Medicine trial treated children with diffuse midline glioma using engineered immune cells. Four patients had tumor volume reduced by more than half, and one tumor disappeared from brain scans.

Then

The results showed CAR-T cells could reach and act on brainstem tumors in children.

Now

The trial established that the approach is testable in pediatric patients, though it was too early to call any patient cured.

Why this matters now

It is the closest existing evidence that this class of therapy can affect human DMG, which B-SYNC will now have to match or beat.

Sources

(4)
ScienceDaily UC San Francisco Stanford Medicine Biohack